LIPO · Lipella Pharmaceuticals Inc.
$0.03
+0.00 (+0.00%)
At close · Jul 29
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Nov 14, 2025
Market Cap
$152,487
Shares
4.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.03
Open$0.03
Day$0.03–0.03
52W$0.02–0.74
Avg vol 30d31K
Short int3K · 0.1% float · 1.0d
Short vol13%
DataDec 2022–Jul 2026
Filing10-Q · Nov 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Nov 14, 2025
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.1 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−83%
below
Price vs 50-day avg
−59%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−71%
trailing
6-month return
−84%
trailing
YTD return
−82%
this year
Relative strength
−90%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.05% of float · ▲ +0.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — 13F breadth
Squeeze score
16
low risk · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
EPS growth
+22%
Y/Y
Free cash flow
$-4.0M
Balance sheet
$2.2M
net cash
Quant / Vol
risk profile
Volatility
409%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
26.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−83%
Bearish
Price vs 50-day avg
−59%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.05% of float · ▲ +0.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $0
Now $0 · 2%
52-wk high $1
vs 200-day avg -83%
vs 50-day avg -59%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIPO
this stock
Lipella Pharmaceuticals Inc.
|
$152,487 | -81.7% | +19.3% | — | 0.1% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.26B | +6.6% | +46.2% | 28.6 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.5 | 3.4% |
|
ARGX
Argenx SE
|
$54.59B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
4
- % held
- 0.1%
- Net QoQ
- -10.6K sh
- Top holder
- Leaf Huang
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIPO | +0.0% | -71.3% | -84.1% | -71.3% | -81.7% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | +2.4% | -69.0% | -90.4% | -69.0% | -88.6% |